Descartes 19
Alternative Names: Descartes-19Latest Information Update: 28 Aug 2023
At a glance
- Originator Cartesian Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Autoimmune disorders; Lymphoma
Most Recent Events
- 03 Jul 2023 Cartesian Therapeutics files for patent protection with forCancer immunotherapy with highly enriched cd8+ chimeric antigen receptor t cells in USA
- 03 Jul 2023 Preclinical trials in Autoimmune disorders in USA (Parenteral) (Cartesian Therapeutics pipeline, July 2023)
- 03 Jul 2023 Preclinical trials in Lymphoma in USA (Parenteral) (Cartesian Therapeutics pipeline, July 2023)